NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $135.68 +5.59 (+4.30 %) (As of 04/25/2019 04:00 PM ET)Previous Close$130.09Today's Range$128.96 - $135.8152-Week Range$92.56 - $141.86Volume1.71 million shsAverage Volume1.58 million shsMarket Capitalization$30.32 billionP/E Ratio19.14Dividend YieldN/ABeta1.55 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Receive ALXN News and Ratings via Email Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALXN Previous Symbol CUSIP01535110 CIK899866 Webwww.alexion.com Phone475-230-2596Debt Debt-to-Equity Ratio0.31 Current Ratio2.88 Quick Ratio2.48Price-To-Earnings Trailing P/E Ratio19.14 Forward P/E Ratio15.92 P/E Growth1.01 Sales & Book Value Annual Sales$4.13 billion Price / Sales7.34 Cash Flow$9.2678 per share Price / Cash Flow14.64 Book Value$41.08 per share Price / Book3.30Profitability EPS (Most Recent Fiscal Year)$7.09 Net Income$77.59 million Net Margins1.88% Return on Equity18.15% Return on Assets11.93%Miscellaneous Employees2,656 Outstanding Shares223,469,000Market Cap$30.32 billion Next Earnings Date4/25/2019 (Confirmed) OptionableOptionable Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions What is Alexion Pharmaceuticals' stock symbol? Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN." How were Alexion Pharmaceuticals' earnings last quarter? Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings results on Thursday, April, 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.19 by $0.20. The biopharmaceutical company earned $1.14 billion during the quarter, compared to analysts' expectations of $1.13 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The company's revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.68 EPS. View Alexion Pharmaceuticals' Earnings History. When is Alexion Pharmaceuticals' next earnings date? Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Alexion Pharmaceuticals. What guidance has Alexion Pharmaceuticals issued on next quarter's earnings? Alexion Pharmaceuticals updated its FY19 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of $9.25-9.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.31. The company issued revenue guidance of $4.675-4.750 billion, compared to the consensus revenue estimate of $4.76 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $9.25-9.45 EPS. What price target have analysts set for ALXN? 15 brokerages have issued twelve-month price targets for Alexion Pharmaceuticals' shares. Their predictions range from $123.00 to $190.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $163.9333 in the next year. This suggests a possible upside of 20.8% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals. What is the consensus analysts' recommendation for Alexion Pharmaceuticals? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals. Has Alexion Pharmaceuticals been receiving favorable news coverage? Media headlines about ALXN stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of Alexion Pharmaceuticals' key competitors? Some companies that are related to Alexion Pharmaceuticals include Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY), Shire (SHPG), Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY) and Takeda Pharmaceutical (TKPYY). What other stocks do shareholders of Alexion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Biogen (BIIB), Allergan (AGN), Amgen (AMGN) and Visa (V). Who are Alexion Pharmaceuticals' key executives? Alexion Pharmaceuticals' management team includes the folowing people: Dr. Ludwig N. Hantson, CEO & Director (Age 56)Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62) Who are Alexion Pharmaceuticals' major shareholders? Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Investec Asset Management LTD (0.75%), Calamos Advisors LLC (0.31%), Strs Ohio (0.29%), Factory Mutual Insurance Co. (0.24%), Peregrine Capital Management LLC (0.07%) and Virginia Retirement Systems ET AL (0.07%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals. Which major investors are selling Alexion Pharmaceuticals stock? ALXN stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Gateway Investment Advisers LLC, Rhenman & Partners Asset Management AB, Calamos Advisors LLC, Empire Life Investments Inc., Investec Asset Management North America Inc., Oppenheimer Asset Management Inc. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, Indrani Lall Franchini, John J Orloff, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals. Which major investors are buying Alexion Pharmaceuticals stock? ALXN stock was acquired by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Virginia Retirement Systems ET AL, BNP Paribas Arbitrage SA, Pacer Advisors Inc., Strs Ohio, Meeder Asset Management Inc., DNB Asset Management AS and Landsberg Bennett & Dubbaneh LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals. How do I buy shares of Alexion Pharmaceuticals? Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Alexion Pharmaceuticals' stock price today? One share of ALXN stock can currently be purchased for approximately $135.68. How big of a company is Alexion Pharmaceuticals? Alexion Pharmaceuticals has a market capitalization of $30.32 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.59 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe. What is Alexion Pharmaceuticals' official website? The official website for Alexion Pharmaceuticals is http://www.alexion.com. How can I contact Alexion Pharmaceuticals? Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected] MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 1,099 (Vote Outperform)Underperform Votes: 604 (Vote Underperform)Total Votes: 1,703MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: What defines an oversold asset?